Subscribe
Numstocker / Shutterstock.com
3 October 2024NewsAmericasMuireann Bolger

Moderna wins reprieve in COVID-19 vaccine dispute

Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Alnylam says Moderna used patented tech to make vaccine
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.
Big Pharma
IP Life Sciences Exchange: a preview
7 November 2016   The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Alnylam says Moderna used patented tech to make vaccine
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.
Big Pharma
IP Life Sciences Exchange: a preview
7 November 2016   The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.

More on this story

Americas
Alnylam says Moderna used patented tech to make vaccine
22 March 2022   Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.
Big Pharma
IP Life Sciences Exchange: a preview
7 November 2016   The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages